Scott Braunstein, MD
Dr. Braunstein serves as an Operating Partner at Aisling Capital. He recently served as Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. During his tenure at Pacira, his role included SVP of Strategy; Chief Strategy Officer, and Chief Operating Officer.
Dr. Braunstein was appointed to the Esperion Board of Directors in June 2015. He has served as member of the Audit Committee since joining Esperion as well as Chairman of the Audit Committee for the past 2 years. Scott serves as Chairman of the Board of Artara Therapeutics and joined the boards and audit committees of Trevena, Marinus, and Ziopharm in 2018.
Earlier in his career, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management. Previously, he spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as a portfolio manager in the Global Healthcare team responsible for managing investments in pharmaceuticals, biotechnology, and medical devices. From 2000 until 2002 he was in healthcare specialty sales at Deutsche Bank. Prior to that, Dr. Braunstein was Vice President of Operations at Defined Healthcare.
Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and for Columbia University Medical Center after completing his training at the New York Hospital/Cornell Medical Center, his research experience at Rockefeller University, and earnin
Stan E. Abel, President and Chief Executive Officer
Stan E. Abel joined SiteOne in February 2014 as President and Chief Executive Officer, bringing to the company more than 20 years of senior management and financial experience. Mr. Abel's background includes successfully leading complex development-stage life science companies, identifying and in-licensing important new pharmaceutical product opportunities, raising more than $100M in capital to fund operations, and providing strategic advisory services to a wide range of development stage biotech companies. Mr. Abel currently serves as a member of the board directors of Adynxx, Inc.
Mr. Abel served as Chief Executive Officer of Corthera, Inc., from October 2007 through the successful sale of the company to Novartis in February 2010. Prior to joining Corthera, he was a founder and Chief Financial Officer of Cerexa, Inc. from its inception in July 2005 through the successful sale of the company to Forest Laboratories in January 2007. Prior to Cerexa‚ he was the Chief Financial Officer of Peninsula Pharmaceuticals, Inc. from January 2003 through the sale of the company to Johnson & Johnson in June 2005.
Earlier in his career‚ Mr. Abel spent four years at Eli Lilly and Company within the finance and strategy organizations. He also held a variety of financial leadership positions during his nine years at DowBrands‚ Inc., a wholly-owned subsidiary of The Dow Chemical Company. He earned a B.S. in business from Indiana University and an M.B.A.‚ with honors‚ from the University of Chicago. He received his CPA from the State of Indiana in 1995.
Justin Du Bois, PhD, Co-founder, Scientific Advisory Board Member
Dr. Du Bois is Associate Professor of Chemistry at Stanford. He received his BS from the University of California Berkeley and his PhD from Caltech and was a postdoctoral fellow at the Massachusetts Institute of Technology. Dr. Du Bois has 20 years of experience in synthetic organic chemistry. His research has been supported by many federal and private grants.
A major research program in Dr. Du Bois’ laboratory is developing novel syntheses of molecules that block the action of voltage-gated sodium ion channels — in particular, structural analogues of the natural product, saxitoxin. Characterization of these analogues furthers our understanding of the neurophysiology of sodium channels and, ultimately, will serve as templates for new agents for diagnosing and treating patients suffering from pain and other sodium channel-mediated diseases.
Dr. Du Bois has consulted for several large pharmaceutical companies on the medicinal chemistry related to the development of novel drugs. His many awards and honors include the Cope Young Scholar Award (American Chemical Society), Corey Young Investigator Award (Pfizer Endowment Fund), Young Investigator Award (Tetrahedron), Mukaiyama Prize (Chemical Society of Japan), and Gunn University Fellowship (Stanford).
Rick Orr joined SiteOne’s board of directors in May 2014 and brings more than 15 years of operational and legal experience in the biotechnology industry.
Mr. Orr serves as President, Chief Executive Officer and board member of Adynxx, a life science company located in San Francisco, California dedicated to developing transformative pain therapies. Prior to joining Adynxx, he served as Chief Operating Officer of Corthera where he led the successful sale of the company to Novartis in February 2010. Prior to his role at Corthera, he was Sr. Vice President, Operations of Cerexa, a wholly-owned subsidiary of Forest Laboratories. Mr. Orr was one of the founders of Cerexa and served as General Counsel until the company was acquired by Forest Laboratories in January 2007.
Earlier in his career, he served as the Associate General Counsel of Peninsula Pharmaceuticals where he played a central role in structuring the acquisition of Peninsula by Johnson & Johnson in June 2005. Prior to working at Peninsula, Rick was an attorney at Cooley LLP. Mr. Orr received a JD magna cum laude from the University of San Francisco School of Law. He received a BA from The Ohio State University and an MA from the University of California, Santa Barbara. He is a member of the State Bar of California.
Mr. Zakrzewski is currently the Chairman of Onxeo. He has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry, serving on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, Insulet Corporation, and Onxeo.
Mr Zakrzewski also serves on the board of a number of privately held companies, is advisor to a number of entities, and is involved in a number of philanthropic activities. He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3 ‘s from 2010 through 2013 successfully developing and launching Vascepa®.
Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 through 2010. Xcellerex was sold to GE Healthcare. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 through 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals was sold to GlaxoSmithKline in 2007.
From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance and business development focused on Lilly’s biotechnology & protein business. His most recent position was Senior Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a worldwide basis. Mr. Zakrzewski, an inventor on multiple US patents, received a BS in Chemical Engineering in 1986 from Drexel University, a MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.
Will Price is the Managing Director of Next Frontier Capital. He founded Next Frontier Capital to partner with mission-driven, talented entrepreneurs to build Montana technology companies of impact, utility, value. Mr. Price's career spans venture capital investing as well as operational, transactional, and advisory roles at both public and private companies.
Prior to Next Frontier Capital, Mr. Price served as CEO of Flite, an advertising and analytics platform. During his six year tenure, he built a market leading organization capable of serving and analyzing billions of ad interactions, sold enterprise customers such as Procter & Gamble, The New York Times, and LinkedIn, raised $24m from leading venture capitalists, including Sequoia Capital, General Catalyst, and strategic customers Conde Nast, Jive Software, and Publicis. Mr. Price continues to serve on the board of Flite. Previously, he served as a Managing Director at Hummer Winblad Venture Partners, where he focused on SaaS and open source. He helped lead investments in Mulesoft, Sonatype, SlideRocket, Flite, among others. Mr. Price joined Hummer Winblad from Pequot Capital, where he focused on software investing. Earlier in his career, he worked for Morgan Stanley in NYC, Hong Kong, and the ASEAN markets focused on the privatization of state-owned assets.
Mr. Price represents Next Frontier Capital on the board of SiteOne Therapeutics and Submittable.
Mr. Price graduated from Harvard College, studied Mandarin at Nanjing University, and earned his M.B.A from Northwestern University, where he graduated at the top of his class.
Lowell Sears, Chairman of the Board
Lowell E. Sears is Chairman and CEO of Sears Capital Management, a venture investment and portfolio management firm specializing in life sciences. He has been an active life science venture investor since 1994, helping to found and fund over 50 companies.
From 1986 until 1994, Mr. Sears was a part of the senior management team of Amgen, Inc., where he held positions of Chief Financial Officer as well as Senior Vice President responsible for the Asia Pacific Region. Prior to joining to Amgen, Mr. Sears held senior planning and financial positions with Atlantic Richfield Company (ARCO) from 1976 until 1986, including a period as Chief Financial Officer for its Ventures Division.
Mr. Sears has served on the boards of twenty two companies, including roles as board chairman and audit committee chair. He currently serves on the board of Vital Therapies, Inc (NASDAQ: VTL) and Halcyon Medical, Inc (Private).